Healthcare / Drug Manufacturers - Specialty & GenericHKSE
$1.60
+0.02 (+1.28%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $2.0B · quality 67.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8.1B
P/E
N/A
•EV/EBITDA
7.4x
↓ROE
-1.7%
↓Gross Margin
48.1%
↓Debt/Equity
0.12
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.0%
FCF CAGR
+51.3%
FCF margin
13.3%
FCF / Net income
-5.72x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $14.74B · net income $-342.1M · FCF $1.96B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $14.74B | $14.74B | $16.51B | $18.12B | $14.30B |
| Net Income | $-342.1M | $-342.1M | $54.1M | $1.29B | $764.5M |
| EBITDA | $894.0M | $894.0M | $1.50B | $2.56B | $2.16B |
| EPS | -0.07 | -0.07 | 0.01 | 0.26 | 0.15 |
| Gross Margin | 48.1% | 48.1% | 47.6% | 51.2% | 50.3% |
| Operating Margin | 4.2% | 4.2% | 5.6% | 7.5% | 8.3% |
| Net Margin | -2.3% | -2.3% | 0.3% | 7.1% | 5.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.12 | 0.12 | 0.19 | 0.24 | 0.25 |
| Current Ratio | 2.29 | 2.29 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.96B | $1.96B | $2.07B | $680.2M | $565.1M |
| Returns | |||||
| ROE | -1.7% | -1.7% | 0.3% | 6.1% | 3.8% |
| Valuation | |||||
| P/E | — | — | 209.35 | 15.13 | 24.70 |
| EV/EBITDA | 7.39 | 7.39 | 7.60 | 8.44 | 9.66 |
| P/B | 0.39 | 0.39 | 0.53 | 0.92 | 0.94 |
| Growth & Yield | |||||
| Revenue Growth | -10.7% | -10.7% | -8.9% | 26.7% | — |
| EPS Growth | -734.6% | -734.6% | -95.8% | 68.1% | — |
| Dividend Yield | 0.2% | 0.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-27.0%
Start / end P/E
n/dx → n/dx
EPS bridge
0.01 → -0.07
Residual
-27.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.